强生Johnson & Johnson (JNJ) 2019年年度报告「NYSE」.pdf

1、2019A N N U A L R E P O R T By just about every measure,Johnson&Johnsons 133rd year was extraordinary.We delivered strong operational revenue and adjusted operational earnings growth*that exceeded the financial performance goals we set for the Company at the start of 2019.We again made record invest

2、ments in research and development(R&D)more than$11 billion across our Pharmaceutical,Medical Devices and Consumer businessesas we maintained a relentless pursuit of innovation to develop vital scientific breakthroughs.We proudly launched new transformational medicines for untreated and treatment-res

3、istant diseases,while gaining approvals for new uses of many of our medicines already in the market.We deployed approximately$7 billion,primarily in transactions that fortify our commitment to digital surgery for a more personalized and elevated standard of healthcare,and that enhance our position i

4、n consumer skin health.And our teams around the world continued working to address pressing public health crises,including HIV,Ebola,and most recently Coronavirusknown as COVID-19.These are some of the many financial and strategic achievements that were made possible by the commitment of our more th

5、an 132,000 Johnson&Johnson colleagues,who passionately lead the way in improving the health and well-being of people around the world.Through proactive leadership across our enterprise,we navigated a constant surge of unique and complex challenges,spanning dynamic global issues,shifting political cl

6、imates,industry and competitive headwinds,and an ongoing litigious environment.As we have experienced for 133 years,we can be sure that 2020 will present a new set of opportunities and challenges.However,propelled by our people,products,and purpose,we look forward to the future with great confidence